Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation

Erica S. Rinella, Yongzhao Shao, Lauren Yackowski, Sreemanta Pramanik, Ruth Oratz, Freya Schnabel, Saurav Guha, Charles Leduc, Christopher L. Campbell, Susan D. Klugman, Mary Beth Terry, Ruby T. Senie, Irene L. Andrulis, Mary Daly, Esther M. John, Daniel Roses, Wendy K. Chung, Harry Ostrer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially true for women at high risk because of family history, but without BRCA1/2 mutations. This study incorporates three datasets in a GWAS analysis of women with Ashkenazi Jewish (AJ) homogeneous ancestry. Two independent discovery cohorts comprised 239 and 238 AJ women with invasive breast cancer or preinvasive ductal carcinoma in situ and strong family histories of breast cancer, but lacking the three BRCA1/2 founder mutations, along with 294 and 230 AJ controls, respectively. An independent, third cohort of 203 AJ cases with familial breast cancer history and 263 healthy controls of AJ women was used for validation. A total of 19 SNPs were identified as associated with familial breast cancer risk in AJ women. Among these SNPs, 13 were identified from a panel of 109 discovery SNPs, including an FGFR2 haplotype. In addition, six previously identified breast cancer GWAS SNPs were confirmed in this population. Seven of the 19 markers were significant in a multivariate predictive model of familial breast cancer in AJ women, three novel SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884(16q22.2)], the FGFR2 haplotype, and three previously published SNPs [rs13387042(2q35), rs2046210(ESR1), and rs3112612(TOX3)], yielding moderate predictive power with an area under the curve (AUC) of the ROC (receiver-operator characteristic curve) of 0.74. Population-specific genetic variants in addition to variants shared with populations of European ancestry may improve breast cancer risk prediction among AJ women from high-risk families without founder BRCA1/2 mutations.

Original languageEnglish (US)
Pages (from-to)523-536
Number of pages14
JournalHuman Genetics
Volume132
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Single Nucleotide Polymorphism
Breast Neoplasms
Genome-Wide Association Study
Mutation
Haplotypes
Aptitude
Carcinoma, Intraductal, Noninfiltrating
Genetic Models
Carcinoma in Situ
Population Genetics
Population
Area Under Curve
History
Familial Breast Cancer

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. / Rinella, Erica S.; Shao, Yongzhao; Yackowski, Lauren; Pramanik, Sreemanta; Oratz, Ruth; Schnabel, Freya; Guha, Saurav; Leduc, Charles; Campbell, Christopher L.; Klugman, Susan D.; Terry, Mary Beth; Senie, Ruby T.; Andrulis, Irene L.; Daly, Mary; John, Esther M.; Roses, Daniel; Chung, Wendy K.; Ostrer, Harry.

In: Human Genetics, Vol. 132, No. 5, 05.2013, p. 523-536.

Research output: Contribution to journalArticle

Rinella, ES, Shao, Y, Yackowski, L, Pramanik, S, Oratz, R, Schnabel, F, Guha, S, Leduc, C, Campbell, CL, Klugman, SD, Terry, MB, Senie, RT, Andrulis, IL, Daly, M, John, EM, Roses, D, Chung, WK & Ostrer, H 2013, 'Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation', Human Genetics, vol. 132, no. 5, pp. 523-536. https://doi.org/10.1007/s00439-013-1269-4
Rinella, Erica S. ; Shao, Yongzhao ; Yackowski, Lauren ; Pramanik, Sreemanta ; Oratz, Ruth ; Schnabel, Freya ; Guha, Saurav ; Leduc, Charles ; Campbell, Christopher L. ; Klugman, Susan D. ; Terry, Mary Beth ; Senie, Ruby T. ; Andrulis, Irene L. ; Daly, Mary ; John, Esther M. ; Roses, Daniel ; Chung, Wendy K. ; Ostrer, Harry. / Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. In: Human Genetics. 2013 ; Vol. 132, No. 5. pp. 523-536.
@article{c7c1ddff8b5b4476bc563cbc9c416e91,
title = "Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation",
abstract = "The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially true for women at high risk because of family history, but without BRCA1/2 mutations. This study incorporates three datasets in a GWAS analysis of women with Ashkenazi Jewish (AJ) homogeneous ancestry. Two independent discovery cohorts comprised 239 and 238 AJ women with invasive breast cancer or preinvasive ductal carcinoma in situ and strong family histories of breast cancer, but lacking the three BRCA1/2 founder mutations, along with 294 and 230 AJ controls, respectively. An independent, third cohort of 203 AJ cases with familial breast cancer history and 263 healthy controls of AJ women was used for validation. A total of 19 SNPs were identified as associated with familial breast cancer risk in AJ women. Among these SNPs, 13 were identified from a panel of 109 discovery SNPs, including an FGFR2 haplotype. In addition, six previously identified breast cancer GWAS SNPs were confirmed in this population. Seven of the 19 markers were significant in a multivariate predictive model of familial breast cancer in AJ women, three novel SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884(16q22.2)], the FGFR2 haplotype, and three previously published SNPs [rs13387042(2q35), rs2046210(ESR1), and rs3112612(TOX3)], yielding moderate predictive power with an area under the curve (AUC) of the ROC (receiver-operator characteristic curve) of 0.74. Population-specific genetic variants in addition to variants shared with populations of European ancestry may improve breast cancer risk prediction among AJ women from high-risk families without founder BRCA1/2 mutations.",
author = "Rinella, {Erica S.} and Yongzhao Shao and Lauren Yackowski and Sreemanta Pramanik and Ruth Oratz and Freya Schnabel and Saurav Guha and Charles Leduc and Campbell, {Christopher L.} and Klugman, {Susan D.} and Terry, {Mary Beth} and Senie, {Ruby T.} and Andrulis, {Irene L.} and Mary Daly and John, {Esther M.} and Daniel Roses and Chung, {Wendy K.} and Harry Ostrer",
year = "2013",
month = "5",
doi = "10.1007/s00439-013-1269-4",
language = "English (US)",
volume = "132",
pages = "523--536",
journal = "Human Genetics",
issn = "0340-6717",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation

AU - Rinella, Erica S.

AU - Shao, Yongzhao

AU - Yackowski, Lauren

AU - Pramanik, Sreemanta

AU - Oratz, Ruth

AU - Schnabel, Freya

AU - Guha, Saurav

AU - Leduc, Charles

AU - Campbell, Christopher L.

AU - Klugman, Susan D.

AU - Terry, Mary Beth

AU - Senie, Ruby T.

AU - Andrulis, Irene L.

AU - Daly, Mary

AU - John, Esther M.

AU - Roses, Daniel

AU - Chung, Wendy K.

AU - Ostrer, Harry

PY - 2013/5

Y1 - 2013/5

N2 - The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially true for women at high risk because of family history, but without BRCA1/2 mutations. This study incorporates three datasets in a GWAS analysis of women with Ashkenazi Jewish (AJ) homogeneous ancestry. Two independent discovery cohorts comprised 239 and 238 AJ women with invasive breast cancer or preinvasive ductal carcinoma in situ and strong family histories of breast cancer, but lacking the three BRCA1/2 founder mutations, along with 294 and 230 AJ controls, respectively. An independent, third cohort of 203 AJ cases with familial breast cancer history and 263 healthy controls of AJ women was used for validation. A total of 19 SNPs were identified as associated with familial breast cancer risk in AJ women. Among these SNPs, 13 were identified from a panel of 109 discovery SNPs, including an FGFR2 haplotype. In addition, six previously identified breast cancer GWAS SNPs were confirmed in this population. Seven of the 19 markers were significant in a multivariate predictive model of familial breast cancer in AJ women, three novel SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884(16q22.2)], the FGFR2 haplotype, and three previously published SNPs [rs13387042(2q35), rs2046210(ESR1), and rs3112612(TOX3)], yielding moderate predictive power with an area under the curve (AUC) of the ROC (receiver-operator characteristic curve) of 0.74. Population-specific genetic variants in addition to variants shared with populations of European ancestry may improve breast cancer risk prediction among AJ women from high-risk families without founder BRCA1/2 mutations.

AB - The ability to establish genetic risk models is critical for early identification and optimal treatment of breast cancer. For such a model to gain clinical utility, more variants must be identified beyond those discovered in previous genome-wide association studies (GWAS). This is especially true for women at high risk because of family history, but without BRCA1/2 mutations. This study incorporates three datasets in a GWAS analysis of women with Ashkenazi Jewish (AJ) homogeneous ancestry. Two independent discovery cohorts comprised 239 and 238 AJ women with invasive breast cancer or preinvasive ductal carcinoma in situ and strong family histories of breast cancer, but lacking the three BRCA1/2 founder mutations, along with 294 and 230 AJ controls, respectively. An independent, third cohort of 203 AJ cases with familial breast cancer history and 263 healthy controls of AJ women was used for validation. A total of 19 SNPs were identified as associated with familial breast cancer risk in AJ women. Among these SNPs, 13 were identified from a panel of 109 discovery SNPs, including an FGFR2 haplotype. In addition, six previously identified breast cancer GWAS SNPs were confirmed in this population. Seven of the 19 markers were significant in a multivariate predictive model of familial breast cancer in AJ women, three novel SNPs [rs17663555(5q13.2), rs566164(6q21), and rs11075884(16q22.2)], the FGFR2 haplotype, and three previously published SNPs [rs13387042(2q35), rs2046210(ESR1), and rs3112612(TOX3)], yielding moderate predictive power with an area under the curve (AUC) of the ROC (receiver-operator characteristic curve) of 0.74. Population-specific genetic variants in addition to variants shared with populations of European ancestry may improve breast cancer risk prediction among AJ women from high-risk families without founder BRCA1/2 mutations.

UR - http://www.scopus.com/inward/record.url?scp=84876470991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876470991&partnerID=8YFLogxK

U2 - 10.1007/s00439-013-1269-4

DO - 10.1007/s00439-013-1269-4

M3 - Article

C2 - 23354978

AN - SCOPUS:84876470991

VL - 132

SP - 523

EP - 536

JO - Human Genetics

JF - Human Genetics

SN - 0340-6717

IS - 5

ER -